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S U M M A R Y
On June 17, 2016, RESIST-TB, IMPAACT, Vital Strategies, and New Ventures jointly hosted the Pediatric
Multidrug Resistant Tuberculosis Clinical Trials Landscape Meeting in Arlington, Virginia, USA. The
meeting provided updates on current multidrug-resistant tuberculosis (MDR-TB) trials targeting
pediatric populations and adult trials that have included pediatric patients. A series of presentations
were given that discussed site capacity needs, community engagement, and additional interventions
necessary for clinical trials to improve the treatment of pediatric MDR-TB. This article presents a
summary of topics discussed, including the following: current trials ongoing and planned; the global
burden ofMDR-TB in children; current regimens forMDR-TB treatment in children; pharmacokinetics of
second-line anti-tuberculosis medications in children; design, sample size, and statistical considerations
for MDR-TB trials in children; selection of study population, design, and treatment arms for a trial of
novel pediatric MDR-TB regimens; practical aspects of pediatric MDR-TB treatment trials; and strategies
for integrating children into adult tuberculosis trials. These discussions elucidated barriers to pediatric
MDR-TB clinical trials and provided insight into necessary next steps for progress in this ﬁeld.
Investigators and funding agencies need to respond to these recommendations so that important studies
can be implemented, leading to improved treatment for children with MDR-TB.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
The global epidemic of multidrug-resistant tuberculosis (MDR-
TB), i.e., Mycobacterium tuberculosis that is resistant to isoniazid
and rifampicin, is a major threat to human health.1 In the past
decade, there have been substantial improvements in our ability to
diagnose and treat MDR-TB; however efforts have mainly focused
on MDR-TB in adults. MDR-TB also has a substantial impact in
children; currently, most MDR-TB (and drug-susceptible TB)
treatment guidelines for children are extrapolated from adult
data and rely on clinical experience instead of controlled trials.
However, differences in the pathophysiology, diagnosis, and
treatment of childhood TB relative to TB in adults are well
described, and have limited the beneﬁt children have received
from recent advances in adult MDR-TB care.2 There are relatively
few trials that have focused speciﬁcally on childhood TB. In order* Corresponding author.
E-mail address: semcanaw@gmail.com (S.E. McAnaw).
http://dx.doi.org/10.1016/j.ijid.2016.11.423
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to address this deﬁcit and begin the process of developing a
science-based framework on which to base recommendations, the
International Maternal Pediatric Adolescent AIDS Clinical Trials
Network (IMPAACT) and Research Excellence to Stop TB Resistance
(RESIST-TB) networks organized a meeting to bring together
investigators and clinicians working in this ﬁeld. The aim was to
summarize the current status of knowledge, identify important
areas of research, and develop plans for future research for
pediatric MDR-TB. This report summarizes the results of this
meeting – the Pediatric MDR-TB Landscape Meeting, held June 17,
2016, in Washington DC.
2. Update on current pediatric MDR-TB studies in progress
Prior to 2008, no clinical trials of MDR-TB treatment had ever
been performed in adults or children, and treatment was based
entirely on clinical opinion.3 Since then, phase 2 clinical trials have
demonstrated the efﬁcacy of three new anti-TB drugs –bedaqui-
line, delamanid, and pretomanid – for the treatment of MDR-TB
and extensively drug-resistant (XDR-TB).4 Moreover, linezolid,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
PK/safety studies in children with MDR-TB disease
Study Intervention Design Target population Aim Sample size
MDR-PK 1 PK and safety of levoﬂoxacin,
moxiﬂoxacin, oﬂoxacin,
amikacin, high-dose isoniazid,
ethionamide, para-
aminosalicylic acid, terizidone,
and cycloserine at routine doses
Observational
cohort
Children 0–2 years, 3–5 years,
6–15 years old; all enrolled
simultaneously
PK, drug–drug interactions, and
safety in children treated for
MDR-TB with/without HIV
co-infection
318
MDR-PK 2 Moxiﬂoxacin, levoﬂoxacin, and
linezolid
Observational
cohort
Children 0–<2 years, 2– <6
years, 6–<12 years, 12–<18
years old
PK, drug–drug interactions, and
safety in children treated for
MDR-TB with/without HIV
co-infection
100
Jansen C211 Bedaquiline in combination with
other second-line agents
Open-label,
single-arm
HIV-uninfected children ages
0–1 year, 2–4 years, 5–11 years,
12–17 years old
PK, safety, and anti-
mycobacterial activity of
bedaquiline in combination with
other second-line drugs
60
IMPAACT P1108 Bedaquiline in combination with
other second-line agents
Open-label,
single-arm
HIV-infected and uninfected
children with MDR-TB under an
FDA IND; children 6–17 years
currently enrolled; children 3–5
years and 0–2 years to follow in
parallel
Dose-ﬁnding and safety study of
bedaquiline in combination with
other second-line drugs
Not yet
enrolling
Otsuka 232 and 233 Delamanid Open-label,
multiple-dose
HIV-uninfected children ages
0–2 years, 3–5 years, 6–11 years,
12–17 years
PK, safety, and tolerability of
delamanid
36
IMPAACT 2005 All-oral, injectable-sparing,
delamanid-based MDR-TB
regimen
Open-label,
single-arm
clinical trial
Children 0–<3 years, 3–<6
years, 6–<12 years, 12–<18
years old
PK, safety, and tolerability of
intervention regimen; assess
effect of HIV and ART on
delamanid PK
Not yet
enrolling
PK, pharmacokinetic; MDR-TB, multidrug-resistant tuberculosis; FDA IND, Food and Drug Administration Investigational New Drug; ART, antiretroviral therapy.
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for MDR-TB) have been recognized to have activity against M.
tuberculosis and therefore to be potential companion agents in new
regimens for MDR-TB treatment.4 This has led to a long-overdue
increase inMDR-TB treatment trials. By 2016, four phase 2 and one
phase 3 MDR-TB treatment trials had been completed,5–9 and an
additional eight phase 2 and eight phase 3 trials were under way.10
While this represents a welcome increase in activity that will
hopefully expand treatment options for MDR-TB, only two of these
trials are enrolling children under the age of 12 years, while one is
enrolling adolescents aged 13–17 years. Thus, there is a substantial
unmet need for data that will guide the treatment of children with
MDR-TB. This meeting reviewed clinical trials and observational
cohort studies of pediatric MDR-TB to identify knowledge gaps and
generate momentum for new studies to address those gaps.
Planned and ongoing pediatric MDR-TB studies can be divided
into two groups. The ﬁrst is treatment studies in which the
pharmacokinetics (PK) and safety in children with MDR-TB are
characterized. The goal of these studies is to deﬁne the optimal
doses for children with TB, taking into account efﬁcacy–toxicity
tradeoffs (shown in Table 1). The second is studies of preventive
therapies, in which pediatric household contacts of MDR-TB
patients are treated to prevent disease (shown in Table 2).Table 2
Trials of MDR-TB preventive therapy in children
Study Intervention Design Target po
V-QUIN Levoﬂoxacin,
6 months
Randomized, double-blind,
placebo-controlled phase
3 trial
Adult, ch
househol
pulmona
TB-CHAMP Levoﬂoxacin,
6 months
Randomized, double-blind,
placebo-controlled phase
3 trial
Children
are house
pulmona
A5300/P2003 Delamanid Open-label, phase 3 trial Adult and
househol
TB patien
MDR-TB, multidrug-resistant tuberculosis.Missing from these tables are studies speciﬁcally evaluating the
efﬁcacy of novel regimens for the treatment of pediatric MDR-TB;
none are ongoing. It is hoped that a better understanding of the PK
and safety of new and existing drugswill lead to the rational design
of trials to evaluate optimized regimens speciﬁcally tailored to
pediatric patients.
3. Global burden of MDR-TB in children
TB remains substantially under-diagnosed among children due
to challengeswithmicrobiological conﬁrmation,11 a dearth of good
diagnostics, and limitations in the recording and reporting of
pediatric TB.12 These challenges are further exacerbated in
children with MDR-TB. Until 2012, the World Health Organization
(WHO) did not provide estimates of the burden of pediatric TB.
Two recent studies have provided evidence that the proportion of
children with MDR-TB reﬂects the proportion of new (i.e., never
previously treated for TB) adult TB cases with MDR-TB in the same
setting.13,14 The ﬁrst estimate of pediatric MDR-TB incidence,
published in 2014 by Jenkins et al., was 32 000 annual incident
cases (3.2% of their overall TB incidence estimate).14 In 2016, Dodd
et al. published an extension of their mathematical model to
estimate the number of children with several different forms ofpulation Aim Sample size
ild, and adolescent
d contacts of
ry MDR-TB patients
Evaluate intervention
compared to placebo for
prevention of MDR-TB in
household contacts
Not yet enrolling
children
<5 years old who
hold contacts of
ry MDR-TB patients
Evaluate efﬁcacy and safety
of levoﬂoxacin compared to
placebo for prevention of
MDR-TB
Not yet enrolling
child (0–17 years)
d contacts of MDR-
ts
Evaluate efﬁcacy and safety
of delamanid compared to
standard-dose isoniazid for
TB prevention
Not yet enrolling
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oped MDR-TB annually (i.e., 2.9% of incident TB cases).
The proportion of children with MDR-TB who are diagnosed,
and the proportion of those children who receive appropriate
treatment, is also unknown. However, it is likely a very small
proportion of the 25 000–32 000 children who develop MDR-TB
annually. Although children who are diagnosed and receive
treatment for MDR-TB are likely to recover and have good
treatment outcomes,16 those who remain undiagnosed have a
high risk of death. A recent literature review from the pre-
treatment era demonstrated highmortality in childrenwho did not
receive treatment for TB. Given the high number of children with
MDR-TB who are untreated, mortality is likely to be signiﬁcant.17
4. Regimens for MDR-TB treatment in children: preclinical–
clinical translation?
To assess whether or not preclinical models can help inform
clinical assessments of anti-TB drugs for children, the character-
istics of TB disease in children must ﬁrst be understood. Pediatric
and adult TB are very different. The clinical manifestations of
pediatric TB are highly variable and roughly correlate with age;
very young children more commonly develop disseminated
disease than older children and adults, and children aged 2–12
years commonly have paucibacillary, non-cavitary disease limited
to the lung or lymph nodes, without caseous necrosis (see
Figure 1). Children over the age of 12 years can present with
adult-like pulmonary disease, often with lung cavitation and high
bacterial burden.2 Since younger children tend to have pauciba-
cillary TB (approximately 30% culture-conﬁrmed and <10%
sputum smear-positive) they can reasonably be expected to
respond to treatment better than adults. Improved treatment
outcomes amongst children with MDR-TB compared to adults are
already achieved despite substantially lower drug exposures in
children for many key second-line drugs. However, this variability
in disease severity, pathology, and mycobacterial burden (104 in
paucibacillary versus 107 to 109 in cavitary disease)18 presents a
challenge for the selection of a single regimen and treatment
duration to test for ‘pediatric MDR-TB’.
A critical concern for successful TB treatment is delivery of
effective drugs at adequate concentrations to the site of disease.
Penetration of TB drugs into macrophages, the central nervous
system, lymphnodes, lung parenchyma, and cavitary contentsmay
be needed for the treatment of pediatricMDR-TB, depending on the
age of the child and his or her associated TB-related pathology.
Penetration coefﬁcients of drugs into these different compart-
ments vary widely.19 Studies assessing the spatial distribution of
anti-TB drugs in relevant preclinical models may help inform the
selection of drugs and/or drug combinations for further testing in
speciﬁc populations (e.g., children with disseminated intracellular
disease, or lymphadenitis or meningitis). Drugs also differ in their[(Figure_1)TD$FIG]Figure 1. Manifestations of pediatric tuberculosis, by age, adapted from Marais
et al.2 Disease in children aged 5–10 years of age is generally rare.ability to protect each other against the emergence of resistance. In
patients with a high bacillary load, chromosomally mediated
resistance is invariably present in a subpopulation of organisms, so
drugs must be given in combination to prevent the emergence of
these pre-existing resistant strains. So for adolescents with
cavitary disease, it is likely that drugs must both penetrate into
cavitary contents and achieve concentrations sufﬁcient to protect
companion drugs against the emergence of resistance in that
compartment. For children with paucibacillary disease, the
number of drugs needed to prevent the emergence of resistance
is unknown, but may be fewer than in adults.
There is no single best animal model for pediatric TB disease. In
the ‘standard’ mouse TB treatment model in BALB/c mice, the
disease is largely intracellular, and the mice do not typically
develop caseous necrosis or cavities, and thus their pathology is
similar to that seen in young children.20 Animal models that
develop necrotic lesions and/or cavitary disease (e.g., so-called
Kramnik (C3HeB/FeJ) mice or select rabbit models) may be more
akin to, and informative of, adolescent TB disease. Thus, no single
animal model has been validated as a pediatric TB treatment
model. Indeed, given the wide spectrum of disease burden and
manifestations, a one-size-ﬁts-all approach to regimen composi-
tion, dosing, and treatment duration for pediatric MDR-TB in both
practice and clinical trials may result in under- or over-treatment
of many children.
5. Pharmacokinetics of second-line anti-TB medications in
children
The approach to studying individual anti-TB medications in
children has been to perform PK and safety studies, to establish
doses in children that achieve exposures similar to those in adults
receiving standard doses, and evaluate safety at those doses.
Extrapolation of mg/kg doses directly from adults to children is
often inappropriate because of age-related changes in drug
disposition and metabolism, also known as ‘developmental
pharmacology’. Speciﬁc studies are therefore needed in children
across the age spectrum (with a particular focus on very young
children in whom drug handling is rapidly changing), and many
important knowledge gaps remain.21 Emerging evidence on
ﬂuoroquinolone PK in children with MDR-TB has shown much
lower exposures in children relative to adults with currently
recommended doses.22–24 Age-speciﬁc PK data for ethionamide,
terizidone, and para-aminosalicylic acid (PAS) are expected soon
(MDR-PK1 study).
Research priorities should be centered on those medications
expected to be components of novel MDR-TB regimens; this
includes levoﬂoxacin, moxiﬂoxacin, linezolid, clofazimine, and the
novel medications bedaquiline and delamanid. Work on optimiz-
ing pediatric doses of levoﬂoxacin, moxiﬂoxacin, and linezolid is
ongoing (MDR-PK2). Data on the PK and safety of delamanid in
children aged 6–17 years have been disseminated, with work
ongoing in younger children, including with a pediatric formula-
tion. Pediatric bedaquiline studies are just starting. Clofazimine PK
is poorly understood in adults, and no data for children are
available, representing an important gap. Of note, PK parameters
and values associated with optimal efﬁcacy for second-line drugs
are poorly deﬁned for adults, so PK targets for children are not well
established. In general, dose-ﬁnding studies aim to identify doses
that give equivalent exposures in adults and children. However,
despite ‘low’ drug exposures of key medications like the
ﬂuoroquinolones, outcomes in children with MDR-TB are good
relative to adults.16 This suggests that children may need less
intense treatment and provides justiﬁcation for an efﬁcacy trial of a
shortened regimen in children with MDR-TB. Few child-friendly
formulations of second-line anti-TB medications exist; however
S.E. McAnaw et al. / International Journal of Infectious Diseases 56 (2017) 194–199 197they are urgently needed to allow accurate and acceptable dosing
to children in the ﬁeld.
6. Design, sample size, and statistical considerations for MDR-
TB trials in children
As with other aspects of TB trials, there are similarities and
differences between studies of children and adults. Phase 3 studies
of TB regimens are typically designed as superiority or non-
inferiority trials. Although a number of design innovations have
been proposed to increase information gained and/or efﬁciency,
speciﬁcally multi-arm multi-stage (MAMS) designs25,26 and
adaptive randomization,27 these designs are dependent on an
easily identiﬁable intermediate outcomemeasure such as 2-month
sputum culture conversion. Since this endpoint cannot be
measured in many children, the usefulness of such innovations
in trial design for studies in children may be limited.
A design issue that is of greater relevance in children is that of
stratiﬁcation by factors that are likely to inﬂuence treatment
outcomes. Since age, extent or type of disease, and severity of
disease are variable in children, these factors should be controlled
for by stratiﬁcation. If regimen effectiveness is expected to vary by
these factors, it may be necessary to perform separate sample size
calculations for each stratum. In some situations a factorial design
may be employed to achieve greater efﬁciency, but this depends on
effects being similar across strata.
An issue that is more prominent in pediatric trials is the
presence of imperfect ﬁnal stage outcomes. By this we are referring
to the lack of clarity about whether a patient’s TB has been cured. If
the diagnosis was clinical (i.e., not conﬁrmedmicrobiologically), or
if a microbiologically conﬁrmed diagnosis required invasive
procedures to establish, it may not be possible to conﬁrm that
the disease has been eradicated; a long post-treatment observation
period without relapse may increase certainty, but at the cost of a
prolonged study timeframe and consequent delay in determining
the success of the investigational treatment. A ﬁnal, more practical
issue faced in TB trials is the inability to blind the study or provide
placebo control for some study agents. For example, replacing an
injectable agent with an equally effective oral drug is highly
desirable; however, an injectable placebo raises ethical issues, and
it would likely be unacceptable to patients and families.
7. Selection of study population, design, and treatment arms
for a trial of a novel pediatric MDR-TB regimen
7.1. Which children to include?
Consideration could be given to treating all children less than
18 years of age (the near universal age of majority), which includes
adolescents, who are frequently neglected and for whom safety is
rarely established. Alternatively, one might include all children
less than 15 years of age, to align with the age brackets used by the
WHO for reporting TB statistics. Finally, a younger age cut-off could
be considered to try to capture those children whose pathophysi-
ology (and drug disposition and metabolism) is most different
from adults. Including all children, irrespective of extent of disease,
is more inclusive and representative. However, speciﬁc issues exist
around the treatment of childrenwithmore limited, paucibacillary
disease, where shorter, less intensive regimens may be possible
and for whom there are clear differences in response to treatment
compared to adults. A useful classiﬁcation system has been
proposed by Wiseman et al. which provides guidance on how to
classify children as having severe vs. non-severe disease.28 It may
be appropriate to include only children with a conﬁrmed diagnosis
(i.e., microbiological conﬁrmation of the presence ofM. tuberculosis
shown to be resistant by genotypic or phenotypic testing), as thisgives an unambiguous entry point and allows changes in
microbiological status to provide microbiological endpoints.
However, this excludes the majority of children with MDR-TB
forwhom the diagnosis ismade clinically. A trial that included only
microbiologically conﬁrmed cases (in whom disease severity or
bacterial burden is often higher) would not be representative of all
children with MDR-TB. Regarding the drug resistance proﬁle, it
may be appropriate to only include children with MDR-TB with
preserved susceptibility to the ﬂuoroquinolones and injectables, as
this is a more homogeneous population, and regimens (both
control and intervention) could be standardized.
7.2. Trial design
It may be appropriate to use the same control and intervention
regimens for all children in the trial, as this will provide simplicity,
improved power to determine endpoints, and transferability into
practice. However, it would likely mean that many children will be
over-treated (children with limited disease and less extensive
resistance) and some may be undertreated (children with
extensive disease and more extensive resistance). Alternatively,
it may be possible to divide children in the trial into different
categories (based on resistance proﬁle, extent of disease, or
whether the diagnosis is microbiologically conﬁrmed or not) and
provide different intervention and control arms to each.
7.3. Composition of regimens
For the control arm, a number of options are available. First, a
standard-duration, traditionalWHO-recommended regimen could
be selected, where all children in the trial receive the same drugs
for the same duration. Standard treatment includes up to 6months
of an injectable and a total duration of 18 months of therapy. A
second option is for all children to have an individualized control
regimen whose component drugs and treatment duration is
designed based on each patient’s disease severity, drug resistance
proﬁle, and response to treatment. Third, a number of distinct, pre-
deﬁned control regimens could be used based on resistance proﬁle
or severity. Finally, the new WHO-endorsed shortened regimen
could be used. This has the advantage of being a 9–12-month
regimen, which may be more desirable for patients and also for
standardization of study endpoints. However, there is limited
experience using this regimen in children, and it is currently only
recommended for patients who have TB caused by isolates that are
known to be susceptible to ﬂuoroquinolones and injectable agents,
or for whom resistance to these drug classes is unlikely.
When designing the intervention regimen it is important to
construct a combination regimen that includes drugs that, together,
achieve the following goals: (1) good early bactericidal activity, (2)
potent sterilizing activity, (3) robustness to resistance, and (4)
adequate penetration into relevant sites of disease. Regimens with
limited drug–drug interactions, both with companion TB drugs and
also with antiretroviral drugs, are also highly desirable. Finally, it is
important to consider how easy the regimen would be to use
programmatically, in terms of procurement, formulations, require-
ment for laboratory or safety testing, shelf life, etc. A ﬂuoroquino-
lone (likely levoﬂoxacin, because it has a limited effect on the QT
interval) plus a novel drug (delamanid or bedaquiline), together
with linezolid and clofazimine provides a potential core set of drugs
in such a regimen. The ﬂuoroquinolone provides potent bactericidal
activity and reduces bacterial burden quickly, the novel drugs have
good sterilizing activity, linezolid has a high barrier to resistance
and protects companion drugs, while clofazimine has good
sterilizing activity.29–31 The addition of other drugs, such as
ethionamide, cycloserine, pyrazinamide, and/or high-dose isoniazid
can be considered following careful assessment of the potential
S.E. McAnaw et al. / International Journal of Infectious Diseases 56 (2017) 194–199198beneﬁts versus safety risks. The duration of therapy in the
intervention arm would need to be considered. With multiple
active drugs, some with good sterilizing efﬁcacy, a shorter duration
of therapy is a realistic possibility. Also, given that children
frequently have paucibacillary disease, a shortened treatment of as
little as 6 months may be more likely to be successful in children
than adults.
8. Practical aspects of a pediatric MDR-TB treatment trial
For pediatric MDR-TB research, disease severity must be
carefully collected and documented, as disease severity will
assuredly inﬂuence treatment outcomes. End-points for such
trials should include sub-analyses of patients with culture-
conﬁrmed disease looking at bacteriological cure, even if the main
study outcome is favorable versus unfavorable outcomes. Other
measures of treatment response may include weight gain, clinical
improvement (symptoms/physical signs), radiological improve-
ment, and changes in potential biomarkers. Given that the adverse
effects (AEs) associated with individual drugs are fairly well-
described and standard treatment commonly causes signiﬁcant
toxicity, it is especially important to carefully measure and report
safety outcomes for new versus control regimens in all pediatric
MDR-TB trials. Lastly, every effort should be made to conﬁrm the
presence of MDR-TB in enrolled patients (to avoid misdiagnosis or
misclassiﬁcation), by employing multiple diagnostic methods,
including culture and phenotypic drug susceptibility testing, as
well as molecular methods such Xpert and line probe assay .
9. Integrating children into adult TB trials
Despite substantial urging by pediatricians, clinical trialists,
and regulatory authorities, subjects under the age of 18 years are
rarely included in phase 3 clinical trials of TB. A recently completed
trial of treatment of TB infection, the PREVENT TB Trial, was
successful in enrolling adults and children as young as 2 years of
age and provides an instructive example of both the challenges and
some potential solutions to this problem.32 PREVENT TB was a
randomized, open-label, non-inferiority trial of once-weekly,
directly-observed rifapentine + isoniazid for 3 months (3HP)
compared to daily self-administered isoniazid for 9 months (9H)
for the treatment of latent TB infection (LTBI) in high-risk
tuberculin skin test (TST) reactors. The target population
comprised TST-positive close contacts of a culture-conﬁrmed TB
case, TST-converters, HIV-infected persons with a positive TST or
close contacts to a TB case regardless of TST, and TST-positive
persons with ﬁbrosis on chest radiography consistent with prior
untreated TB. The primary aim of the study was to evaluate the
effectiveness of weekly 3HP versus daily 9H in preventing
progression to TB disease.
The study started enrolling adults and children aged 12–17
years in 2001, as there were no PK data available to guide dosing in
younger children. Doses were subsequently established for
younger children in PK/safety studies, and in 2005 the protocol
was amended to include children aged 2–11 years. Final accrual of
children was achieved by 2010, and collaboration with a pediatric
clinical trials network (IMPAACT) facilitated enrolment of a large
number of children. The study found 3HP to be as well-tolerated
and as effective as 9H for preventing TB in children; 3HP had
signiﬁcantly higher treatment completion rates and was less
hepatotoxic. Revision of the Centers for Disease Control and
Prevention (CDC) LTBI guidelines to allow 3HP for children ages 2–
11 years is now under consideration. Ideally, children should be
included from the outset. However, if this is not feasible, it may be
possible to start the trial in adults butwith a clear plan to gather PK
and safety data while the trial starts, and then subsequentlyinclude children when PK data are available. It would also be
possible to do age de-escalation, where adults are initially
included, with older children then younger children included
later. There is little reason to exclude persons >12 years old from
any adult trial.
10. Conclusions
The topics identiﬁed in this report identify the critical issues in
pediatric MDR-TB that need to be addressed and provide a
blueprint for moving forward. Investigators and funding agencies
need to respond to this agenda so that important studies can be
implemented, leading to improved treatment for children with
MDR-TB.
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